Consilient Health to launch Cytisine smoking cessation treatment in UK
Betsy Goodfellow | January 8, 2024 | News story | Sales and Marketing |Â Â Cytisine, Smoking Cessation, consilient health, smoking cessationÂ
Consilient Health has announced that it plans to launch Cytisine 1.5mg tablets in the UK on 22 January 2024. The drug is a proven and effective prescription treatment for smoking cessation.
Cytisine is a nicotine receptor partial agonist based on a plant alkaloid, which binds to the α4β2 nicotinic acetylcholine receptor, therefore reducing the impact of nicotine on dopamine release, while also decreasing withdrawal symptoms usually incurred from attempts to stop smoking.
The drug has been used for this purpose for decades outside of the UK, so its launch comes with over 50 years of real-world patient data; in both clinical trials and real-world use the drug has been well-tolerated and effective in helping with smoking cessation.
Luke Crosbie, chief executive officer at Consilient Health, commented: “This launch marks a meaningful step forward in enhancing public health. This medication not only offers a tried and tested solution for smoking cessation but also signifies our dedication to providing accessible healthcare options. Consilient Health is proud to contribute to the UK’s goal of a smoke-free future and remains dedicated to bringing forward treatments that can make a real difference in people’s lives.”
Dr Richard Russell, consultant chest physician and clinical reader in respiratory medicine at King’s College London, UK, added: “The arrival of Cytisine is a major advancement in our efforts to assist smokers in quitting. It provides a new hope for many who have struggled to quit smoking in the past and a clear next step for healthcare professionals helping them. This is a positive step towards improving the health outcomes of smokers and reducing the burden of smoking-related diseases.”
Betsy Goodfellow
Related Content
NICE greenlights Consilient Health’s Elmiron for bladder pain syndrome
NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of …
Generic version of Pfizer’s Lyrica launched
A UK pharma firm has launched a cut-price version of Pfizer’s Lyrica along with a …
Study claims cardiovascular risk to Pfizer’s Champix
Pfizer has been drawn into a war of words over its smoking cessation drug Champix …
